Sat.Jun 29, 2024 - Fri.Jul 05, 2024

article thumbnail

Drug’s unique mechanism of action targets schizophrenia abnormalities

Drug Discovery World

Newron Pharmaceuticals has reported new findings of mechanism of action that indicate its drug candidate evenamide could be uniquely effective in patients with treatment resistant schizophrenia (TRS). The drug’s unique mechanism of action targets the core abnormalities in patients with schizophrenia and reduces hippocampal dopaminergic activity, improving symptoms of psychosis, social interactions and cognition.

article thumbnail

A breakthrough in inexpensive, clean, fast-charging batteries

Science Daily: Pharmacology News

Scientists have created an anode-free sodium solid-state battery. This brings the reality of inexpensive, fast-charging, high-capacity batteries for electric vehicles and grid storage closer than ever.

139
139
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

A hybrid evaluation of the intestinal absorption performance of compounds from molecular structure

Chemical Biology and Drug Design

The QSPR model accurately predicted the intestinal absorption of molecules, and the computer simulation found the mechanism of molecular structure affecting intestinal absorption. Abstract Intestinal absorption of compounds is significant in drug research and development. To evaluate this efficiently, a method combining mathematical modeling and molecular simulation was proposed, from the perspective of molecular structure.

article thumbnail

Cartesian data add to progress, questions for CAR-T in autoimmune disease

BioPharma Drive: Drug Pricing

The company claimed Phase 2 study results prove the therapy’s promise treating myasthenia gravis. But shares lost more than a quarter of their value amid questions about the data.

Disease 124
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

New Scandinavian ALS drug research collaboration

Drug Discovery World

The Division of Clinical Neuroscience at Oslo University Hospital (OUS) and the Swedish drug development company TikoMed have signed a research collaboration agreement focused on amyotrophic lateral sclerosis (ALS). TikoMed has previously completed and reported on two successful Phase IIa clinical studies in ALS, one at the Sahlgrenska University Hospital in Sweden and one at the University of Birmingham in the UK, both with promising results.

article thumbnail

New and improved camera inspired by the human eye

Science Daily: Pharmacology News

Computer scientists have invented a camera mechanism that improves how robots see and react to the world around them. Inspired by how the human eye works, their innovative camera system mimics the tiny involuntary movements used by the eye to maintain clear and stable vision over time.

137
137

More Trending

article thumbnail

Lilly drug for Alzheimer’s approved by FDA

BioPharma Drive: Drug Pricing

The drug, which Lilly will sell as Kinsunla, carries a warning for the risk of a certain kind of imaging abnormality that can be serious in rare cases.

FDA 135
article thumbnail

Proscia teams up with Nucleai to improve access to AI biomarkers

Drug Discovery World

Software company Proscia has partnered with spatial AI biomarker company Nucleai in a collaboration aimed at improving precision medicine biomarkers for clinical trials. The companies are integrating Nucleai’s predictive biomarker solutions into Proscia’s Concentriq software platform and will make them available as part of Proscia’s precision medicine AI portfolio.

article thumbnail

Scientists discover new T cells and genes related to immune disorders

Science Daily: Pharmacology News

Researchers have discovered several rare types of helper T cells that are associated with immune disorders such as multiple sclerosis, rheumatoid arthritis, and even asthma. The discoveries were made possible by a newly developed technology they call ReapTEC. The new T cell atlas is publicly available and should help in the development of new drug therapies for immune-mediated diseases.

Therapies 129
article thumbnail

Use of 'Benzo' Sedatives Like Valium, Xanax Won't Raise Dementia Risk: Study

Drugs.com

TUESDAY, July 2, 2024 -- Benzodiazepines do not appear to increase dementia risk, but could have subtle long-term effects on brain structure, a new study reports.Researchers found no link between use of the sedative drug and a higher risk of.

Drugs 119
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

5 FDA decisions to watch in the third quarter

BioPharma Drive: Drug Pricing

Multibillion-dollar buyouts from Bristol Myers Squibb and Gilead could yield new drugs for brain and liver diseases, while a new cell therapy may reach market.

FDA 124
article thumbnail

CatSci acquires chromatography provider Reach Separations

Drug Discovery World

CatSci has acquired Reach Separations, a specialist chromatography provider for the analysis and purification of therapeutics. The acquisition was supported by Keensight Capital, private equity managers dedicated to pan-European Growth Buyout investments. Headquartered in the UK, and with laboratories in both the UK and France, Reach Separations specialises in chromatography for the analysis and purification of chiral and achiral therapeutics.

article thumbnail

Giant salamander-like creature was a top predator in the ice age before the dinosaurs

Science Daily: Pharmacology News

Meet Gaiasia jennyae, the swamp creature with a toilet seat-shaped head. It lived 40 million years before the first dinosaurs, and it was the top predator in its ecosystem.

121
121
article thumbnail

The Effects the ICH E6(R3) Updates Will Have on Good Clinical Practice

Quanticate

Good Clinical Practice (GCP) affects a variety of entities, including sponsors, contract research organisations (CROs), and investigator sites. It’s essential for maintaining ethical standards, high-quality outcomes and facilitating global standardisation, enabling multi-center and multinational studies, thereby streamlining the development and approval process for new medical treatments, and maintaining public trust in clinical research.

article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

FDA Approves New Drug to Treat Alzheimer's, Kisunla

Drugs.com

TUESDAY, July 2, 2024 -- A new drug to treat Alzheimer's disease was approved by the U.S. Food and Drug Administration on Tuesday. In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking declines among patients in the early.

article thumbnail

Gene therapy trial starts in early-onset dementia

Drug Discovery World

AviadoBio has launched its Phase I/II ASPIRE-FTD clinical trial at the Ohio State University in the US. ASPIRE-FTD is evaluating investigational gene therapy AVB-101 in people with frontotemporal dementia (FTD) with progranulin (GRN) gene mutations (FTD-GRN). The study is also recruiting in Europe with study sites in the Netherlands, Poland, and Spain, with additional sites expected to open in multiple countries.

Therapies 147
article thumbnail

An ant that selectively amputates the infected limbs of wounded sisters

Science Daily: Pharmacology News

Saving lives through surgery is no longer exclusive to humans. Scientists now detail how Florida carpenter ants, a common, brown species native to its namesake, selectively treat the wounded limbs of fellow nestmates -- either by wound cleaning or amputation. When experimentally testing the effectiveness of these 'treatments,' not only did they aid in recovery, but the research team found the ants' choice of care catered to the type of injury presented to them.

Treatment 120
article thumbnail

Supercharge Customer Journeys with Salesforce OmniStudio

Perficient: Drug Development

In today’s digital landscape, delivering exceptional customer experiences is paramount. Salesforce OmniStudio empowers you to create engaging, personalized, and brand-consistent interactions across all touchpoints. This blog post delves into OmniStudio, exploring its capabilities, benefits, and how you can leverage it to elevate your customer journeys.

article thumbnail

Most Americans Don't Know That Family Doctors Can Prescribe Anti-Opioid Meds

Drugs.com

TUESDAY, July 2, 2024 -- Most people addicted to opioids and their loved ones are unaware that their primary care doctor can prescribe a medication to treat the disorder, a new nationwide survey reveals."We've made great strides in making it easier.

Doctors 116
article thumbnail

Amgen reports positive results for treatment of IgG4-RD

Drug Discovery World

Amgen has reported positive topline results from its randomised, double-blind, multicentre, placebo-controlled Phase III clinical trial evaluating the efficacy and safety of its treatment for Immunoglobulin G4-related disease (IgG4-RD). The company’s MITIGATE study was designed to evaluate the safety and efficacy of UPLINZA compared to placebo in reducing the risk of flares in adults with IgG4-RD.

Treatment 147
article thumbnail

Organic material from Mars reveals the likely origin of life's building blocks

Science Daily: Pharmacology News

Two samples from Mars together deliver clear evidence of the origin of Martian organic material. The study presents solid evidence for a prediction made over a decade ago that could be key to understanding how organic molecules, the foundation of life, were first formed here on Earth.

118
118
article thumbnail

Eisai and Bristol Myers cancel cancer ADC deal

BioPharma Drive: Drug Pricing

The Japan-based drugmaker said its U.S. partner’s “portfolio prioritization efforts” led to the termination. It will refund part of an upfront payment.

113
113
article thumbnail

Women Less Likely to Get a 'Secondary Condition' Fixed During a Heart Surgery

Drugs.com

MONDAY, July 1, 2024 -- You're getting heart surgery, but your surgeon notices a new anomaly that perhaps could be fixed at the same time.That's more likely to happen if you're a man than a woman, new studies find.The findings came as little.

116
116
article thumbnail

How does circVec technology compare to conventional mRNA expression? 

Drug Discovery World

Circio has announced updated in vivo data that demonstrates a substantial durability advantage of Circio’s circVec technology over conventional mRNA expression. In addition, Circio has undertaken sequence optimisation resulting in a new circVec 2.2 design. “The circVec 2.1 design is performing very well in vivo , and Circio has now validated expression for up to five months.

RNA 147
article thumbnail

This desert moss has the potential to grow on Mars

Science Daily: Pharmacology News

The desert moss Syntrichia caninervis is a promising candidate for Mars colonization thanks to its extreme ability to tolerate harsh conditions lethal to most life forms. The moss is well known for its ability to tolerate drought conditions, but researchers now report that it can also survive freezing temperatures as low as 196 C, high levels of gamma radiation, and simulated Martian conditions involving these three stressors combined.

Research 117
article thumbnail

Moderna gets US funding for bird flu vaccine development

BioPharma Drive: Drug Pricing

BARDA will provide Moderna with $176 million to advance late-stage testing of an H5 influenza shot, as health officials monitor animal outbreaks.

Vaccine 114
article thumbnail

All Diamond Shruumz Edibles Recalled Over High Levels of Mushroom Toxin in Products

Drugs.com

MONDAY, July 1, 2024 -- All Diamond Shruumz edibles have been recalled after the company found high levels of a mushroom toxin in them that may have sickened 39 people in 20 states.The recall includes Diamond Shruumz cones, chocolate bars and.

article thumbnail

Meet the Researcher: Nicola McCarthy, Milner Therapeutics Institute

Drug Discovery World

DDW’s Megan Thomas talks to Nicola McCarthy, Head of Research at the Milner Therapeutics Institute. MT: Could you start by giving me your name, your job title and what you do? NM: I’m Head of Research at the Milner Therapeutics Institute, which is part of the University of Cambridge, and I oversee both wet and dry labs of the institute. MT: Can you provide a top-line summary of your research?

Research 147
article thumbnail

Neutrons on classically inexplicable paths

Science Daily: Pharmacology News

Is nature really as strange as quantum theory says -- or are there simpler explanations? New neutron measurements prove: It doesn't work without the strange properties of quantum theory.

112
112
article thumbnail

How can pharmaceutical marketing evolve with generic entry? The example of Lipitor

Drug Patent Watch

Lipitor’s marketing strategy underwent a significant evolution as generic competition emerged, employing aggressive tactics to retain market share and brand […] Source

Marketing 105
article thumbnail

When It Comes to Weight Gain, Not All Antidepressants Are the Same

Drugs.com

WEDNESDAY, July 3, 2024 -- Weight gain is a common side effect of antidepressants, but some types cause people to pack on pounds more than others, a new study says.Bupropion users are 15% to 20% less likely to gain a significant amount of weight.

110
110
article thumbnail

UK 2024 election: A vote for drug discovery

Drug Discovery World

By DDW Editor Reece Armstrong The upcoming general election in the UK has placed the priorities of the country into the spotlight and the drug discovery sector should in no way be forgotten. Economic uncertainty, challenging global conditions and a healthcare system facing serious pressures, means that whatever government takes the reigns come 4 July, they’ll be indebted with numerous burdens.

article thumbnail

How our brains develop facial recognition skills: New face-detecting brain circuit

Science Daily: Pharmacology News

Scientists have uncovered a brain circuit in primates that rapidly detects faces. The findings help not only explain how primates sense and recognize faces, but could also have implications for understanding conditions such as autism, where face detection and recognition are often impaired from early childhood.

110
110
article thumbnail

DrugPatentWatch Week in Review

Drug Patent Watch

Patent Expirations and Generic Competition This week saw several major blockbuster drugs facing patent expirations, potentially opening the market for […] Source